The injectable GLP-1 analogues do not form a homogeneous therapeutic block. Semaglutide, liraglutide, and tirzepatide differ in their pharmacokinetics, receptor targets, and reimbursement conditions in France. Understanding these distinctions allows for an informed choice with the prescriber, away from the media noise surrounding injections for weight loss.
Tirzepatide and GIP/GLP-1 Dual Agonism: A Mechanism Distinct from Semaglutide
Tirzepatide (Mounjaro) is distinguished from semaglutide (Wegovy, Ozempic) by its dual agonism of GIP and GLP-1 receptors. GIP (glucose-dependent insulinotropic polypeptide) amplifies the insulin secretory response and acts on adipocyte lipid metabolism, opening a weight loss channel absent in mono-agonists.
We observe that this dual action results in greater weight loss in cohorts treated with tirzepatide compared to semaglutide alone. An analysis reported by Sciences et Avenir confirms that the most effective GLP-1 treatments are also those that generate the most side effects, necessitating close monitoring.
For practitioners seeking to document injections for effective weight loss, the mono/dual agonist distinction remains the primary criterion for pharmacological selection.
Reimbursement Conditions in France Since June 2026: Real Prescription Criteria
Since June 15, 2026, Wegovy and Mounjaro are reimbursed at 65% by the Health Insurance. Public websites rarely mention the actual level of requirement for eligibility criteria.
- BMI ≥ 40 kg/m² without comorbidity, or BMI ≥ 35 kg/m² with at least one associated comorbidity (type 2 diabetes, sleep apnea, hypertension).
- Documented failure of at least six months of well-conducted nutritional management, with less than 5% weight loss achieved.
- Initial prescription reserved for specialized obesity structures (CSO, CHU, level 2 or 3 medicine/nutrition services), not for the general practitioner in the community.
This second-line pathway effectively excludes the majority of individuals with simple overweight. Renewal can be ensured in community medicine, but the entry point remains hospital or hospital-university.
Profile of Adverse Effects: How Digestive Tolerance Changes Monitoring
Nausea, vomiting, and diarrhea affect a significant proportion of patients on GLP-1 analogues, especially during the titration phase. These digestive disorders are not trivial: they condition adherence and, by extension, treatment effectiveness.
Gradual titration over several weeks reduces the incidence of gastrointestinal effects, but does not eliminate them. We recommend concurrent dietary monitoring to adapt meal frequency and food texture during dose escalation.
A suspicion of more serious side effects has been recently reported by doctors, according to Top Santé. This type of pharmacovigilance signal reminds us that these molecules remain prescription medications, not comfort devices.
Muscle Mass Loss Under Treatment
An underestimated point in public communication: rapid weight loss under GLP-1 does not distinguish between adipose tissue and lean mass. Without appropriate physical activity, induced sarcopenia can degrade body composition despite a favorable balance.
Protocols combining muscle resistance and calibrated protein intake should be integrated from the initiation of treatment, not as a catch-up six months later.
Quality of Life and Treatment Discontinuation: The Missing Data in the Current Discourse
Euronews Health reported in July 2026 that obesity medications lead to weight loss but do not necessarily improve quality of life. This observation significantly nuances the narrative of a therapeutic “revolution.”
Weight regain after treatment cessation is documented. These injections do not reprogram the basal metabolism: they work as long as they are administered. The question of long-term treatment, potentially for life, arises for each patient, with its financial and psychological implications.
Oral Semaglutide: An Alternative in Development
Oral formulations of semaglutide already exist for type 2 diabetes. Their extension to weight indication could change the landscape, removing the barrier of weekly injection. For now, injection remains the validated route of administration for obesity in France.
Liraglutide and Orlistat: Residual Positioning Against New GLP-1s
Liraglutide (Saxenda) requires a daily injection, compared to a weekly injection for semaglutide and tirzepatide. This adherence constraint places it at a disadvantage in the current hierarchy of prescriptions.
Orlistat, on the other hand, acts by inhibiting pancreatic lipases and is not a GLP-1 analogue. Its weight loss efficacy is significantly lower. The combination of naltrexone/bupropion (tablets) targets a different mechanism, centered on the reward circuit, but remains marginal in practice compared to the rise of injectable GLP-1s.
The choice between these molecules depends on the patient’s metabolic profile, comorbidities, and the prescribing structure. Self-medication through parallel circuits exposes individuals to risks of inappropriate dosing and lack of pharmacovigilance monitoring, a problem that health authorities have been closely monitoring since the media hype around these treatments.
